Psoriasis Vulgaris Exacerbation during Treatment with a PD-1 Checkpoint Inhibitor: Case Report and Literature Review

by Marlies De Bock, Eva Hulstaert, Vibeke Kruse, Lieve Brochez
Published 2018-08-01

Challenging PD-L1 expressing cytotoxic T cells as a predictor for response to immunotherapy in melanoma

by Lieve Brochez, Annabel Meireson, Inès Chevolet, Nora Sundahl, Piet Ost, Vibeke Kruse
Published 2018-07-01

Epidermal Acyl-CoA-binding protein is indispensable for systemic energy homeostasis

by Ditte Neess, Vibeke Kruse, Ann-Britt Marcher, Mie Rye Wæde, Julie Vistisen, Pauline M. Møller, Rikke Petersen, Jonathan R. Brewer, Tao Ma, Georgia Colleluori, Ilenia Severi, Saverio Cinti, Zach Gerhart-Hines, Susanne Mandrup, Nils J. Færgeman
Published 2021-02-01

Immune Monitoring in Melanoma and Urothelial Cancer Patients Treated with Anti-PD-1 Immunotherapy and SBRT Discloses Tumor Specific Immune Signatures

by Annabel Meireson, Simon J. Tavernier, Sofie Van Gassen, Nora Sundahl, Annelies Demeyer, Mathieu Spaas, Vibeke Kruse, Liesbeth Ferdinande, Jo Van Dorpe, Benjamin Hennart, Delphine Allorge, Filomeen Haerynck, Karel Decaestecker, Sylvie Rottey, Yvan Saeys, Piet Ost, Lieve Brochez
Published 2021-05-01

Checkpoint inhibition in combination with an immunoboost of external beam radiotherapy in solid tumors (CHEERS): study protocol for a phase 2, open-label, randomized controlled tri...

by Mathieu Spaas, Nora Sundahl, Eva Hulstaert, Vibeke Kruse, Sylvie Rottey, Daan De Maeseneer, Veerle Surmont, Annabel Meireson, Lieve Brochez, Dries Reynders, Els Goetghebeur, Robbe Van den Begin, Dirk Van Gestel, Vincent Renard, Piet Dirix, Pieter Mestdagh, Piet Ost
Published 2021-05-01